Intelligence · Clinical Development
Pipeline search results
Programs matching “Astra” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 467 pipeline programs matching "Astra" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Durvalumab
AstraZeneca
Cancer
1 trial -
Durvalumab + SoC chemotherapy
AstraZeneca
Carcinoma, Non-Small-Cell Lung
1 trial -
EMERALD-1
AstraZeneca AB
Locoregional Hepatocellular Carcinoma (HCC)
1 trial -
Experimental: Tezepelumab
AstraZeneca
Asthma
1 trial -
GEMCITABINE for Patients with histologically or…
AstraZeneca AB
Patients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladder
1 trial -
Gefitinib
AstraZeneca
Non-Small-Cell Lung Carcinoma
1 trial -
Gefitinib
AstraZeneca
NSCLC
1 trial -
Gemcitabine
AstraZeneca
Biliary Tract Cancer
1 trial -
IMFINZI 50 mg/mL concentrate for solution for infusion.
AstraZeneca
small cell lung cancer
1 trial -
IRIS, D3466C00001
AstraZeneca AB
Active Proliferative Lupus Nephritis
1 trial -
JOURNEY
AstraZeneca AB
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
KOMET D134BC00001
AstraZeneca AB
Neurofibromatosis Type 1 (NF1) with Symptomatic, Inoperable Plexiform Neurofibromas (PN).
1 trial -
MEDI4736
AstraZeneca
Squamous Cell Carcinoma of the Head and Neck
1 trial -
MEDI4736
AstraZeneca
Non-Small Cell Lung Cancer
1 trial -
MEDI4736 (Durvalumab)
AstraZeneca
Non-Small-Cell Lung Carcinoma NSCLC
1 trial -
MK-2400-001
Merck Sharp and Dohme
Metastatic Castration-Resistant Prostate Cancer
1 trial -
MK-5684-003
Merck Sharp and Dohme
Metastatic castration resistant prostate cancer
1 trial -
MK-5684-004
Merck Sharp and Dohme
Metastatic castration resistant prostate cancer
1 trial -
Medi-546
AstraZeneca
Systemic Lupus Erythematosus
1 trial -
Metformin
AstraZeneca
Type 2 Diabetes
1 trial -
NKTR-118
AstraZeneca
Opioid-Induced Constipation
1 trial -
NXY-059
AstraZeneca
Cerebral Stroke
1 trial -
OLAPARIB
AstraZeneca
Platinum Sensitive Relapsed Ovarian Cancer
1 trial -
Olaparib
AstraZeneca
Breast Cancer Metastatic
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.